AKUMS2025-01-012025-03-31AKUMS2025-03-31AKUMS2024-03-31AKUMS2024-04-012025-03-31AKUMS2025-01-012025-03-31in-capmkt:OtherExpenses1MemberAKUMS2025-01-012025-03-31in-capmkt:OtherExpenses2MemberAKUMS2024-04-012025-03-31in-capmkt:OtherExpenses1MemberAKUMS2024-04-012025-03-31in-capmkt:OtherExpenses2MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments1MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments2MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments3MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments4MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments5MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments6MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments1MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments2MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments3MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments4MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments5MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments6MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments1MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments2MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments3MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments4MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments5MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments6MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments1MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments2MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments3MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments4MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments5MemberAKUMS2024-04-012025-03-31in-capmkt:ReportableSegments6MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments1MemberAKUMS2025-03-31in-capmkt:ReportableSegments1MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments2MemberAKUMS2025-03-31in-capmkt:ReportableSegments2MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments3MemberAKUMS2025-03-31in-capmkt:ReportableSegments3MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments4MemberAKUMS2025-03-31in-capmkt:ReportableSegments4MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments5MemberAKUMS2025-03-31in-capmkt:ReportableSegments5MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments6MemberAKUMS2025-03-31in-capmkt:ReportableSegments6MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments1MemberAKUMS2025-03-31in-capmkt:ReportableSegments1MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments2MemberAKUMS2025-03-31in-capmkt:ReportableSegments2MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments3MemberAKUMS2025-03-31in-capmkt:ReportableSegments3MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments4MemberAKUMS2025-03-31in-capmkt:ReportableSegments4MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments5MemberAKUMS2025-03-31in-capmkt:ReportableSegments5MemberAKUMS2025-01-012025-03-31in-capmkt:ReportableSegments6MemberAKUMS2025-03-31in-capmkt:ReportableSegments6MemberAKUMS2025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1AKUMS2024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1AKUMS2025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares544222AKUMSNOTLISTEDINE09XN01023AKUMS DRUGS AND PHARMACEUTICALS LIMITEDMain BoardEquity2024-04-012025-03-312025-05-262025-05-19INRMillionsQuarterlyFourth quarterMulti segment2025-05-2614:00:002025-05-2616:42:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated10555470000175450000107309200006238450000194900000-4249000018389700004542000039997000013865100001006173000066919000082170000751360000181930000-926630000-7447000000149606000000001496060000-10160000148590000014761700001989000014659600001994000030621000030163.939.649.64009.649.642024-04-012025-03-31AuditedConsolidated4118158000052122000041702800000225360800001814730000-164700007158210000346000000153446000050442300003841724000032855600001669700003452530000797490000-782730000147600000343777000000003437770000-10950000342682000033817600005601000033707300005609000030621000030163.93022.622.60022.622.6Fair value changes to financial instruments0Other Expenses1386510000Fair value changes to financial instruments-38670000Other Expenses5082900000139017700001596170000206300005131000031720000143000003355600003369900002080650000369090000183883300006809310000077029600001011910000475260000004812800001394875000019880300002274609000041134420000306210000301639300003047014000016597000030636110000034244000034244000035897000018616000067327000015608400001365500007720300005655820000642785000014055700007969970000391410000572080000401000089374700001049831000041134420000Property, Plant and Equipment also includes Right of use asset of Rs. 1614.91 million. <BR> Other Non-Current Asset includes Non-Current Tax Asset of Rs. 123.08 million. <BR> Non-Current Lease Liability of Rs. 673.27 million is shown in other non-current liabilities. <BR> Current Lease liability of Rs. 72.30 million is shown with Other Current Financial Liability. <BR> CDMO8397600000API501440000Domestic Branded Formulations1036520000International Branded Formulations396950000Trade Generics222960000Inter-segment eliminations0CDMO32078760000API2192960000Domestic Branded Formulations4335880000International Branded Formulations1426130000Trade Generics1147850000Inter-segment eliminations01055547000041181580000001055547000041181580000CDMO561380000API-139430000Domestic Branded Formulations217610000International Branded Formulations83410000Trade Generics-104060000Inter-segment eliminations0CDMO3323830000API-757100000Domestic Branded Formulations745740000International Branded Formulations257880000Trade Generics-306330000Inter-segment eliminations0618910000326402000030370000282560000-80650000-3041000006691900003285560000CDMO27016490000API4575970000Domestic Branded Formulations734810000International Branded Formulations813350000Trade Generics739400000Inter-segment eliminations-73572000033144300000799029000041134590000CDMO7280970000API601480000Domestic Branded Formulations1100830000International Branded Formulations512210000Trade Generics432800000Inter-segment eliminations-7357300009192560000130575000010498310000346000000-5057100003410500000-49300000000001192300000000153446000003329700000626080000000015600000-3867000000-168160000-3481000003148110000660064000000-249860000831610000-8672200004651950000000000008547000027231200000000000000000000002498600000-3090640000-547843000000637371000000000-35404000001238600000584180000028264000000727890000-985900000-9859000011105000001011910000Items that will not be reclassified to profit and loss-12550000-12550000Items that will not be reclassified to profit and loss-13620000-13620000-2390000-267000000-10160000-10950000AuditedtrueWalker Chandiok & Co LLPtrue2025-05-31